About Tonix Pharmaceuticals Holding Corp
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.tonixpharma.com/
Frequently Asked Questions
What is the 52-week range for TNXP?
The 52-week high is $25.5 and the 52-week low is $9.19.
What is the P/E ratio for TNXP?
The P/E ratio data is currently unavailable.
What is the dividend yield for TNXP?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -68.99%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -548.64%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.81.
Analyst Recommendation Trends
Wall Street analyst consensus for TNXP over the last few months:
Latest TNXP News
Tonix Pharmaceuticals Says Dr. Reddy's Files ANDA With Paragraph IV Patent Certification For Generic TONMYA On Oct 1; Paragraph IV Certification Challenges Four TONMYA Patents Listed In FDA Orange Book; Co Intends To Enforce TONMYA Intellectual Property Rights
On October 1, 2026, Tonix Pharmaceuticals Holding Corp. (the "Company") received a notice (the "Notice") from Dr. Reddy’s Laboratories Ltd. and Dr. Reddy’s Laboratories, Inc. (collectively,
Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®
New agreement, effective immediately, adds approximately 21 million Medicare lives (38% of approximately 55 million Medicare lives in the U.S.) Commercial and government payer coverage for TONMYA now reaches approximately 166 million covered lives (53% of total U.S. lives) BERKELEY HEIGHTS, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or “the Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced a second
Tonix Pharmaceuticals Announces Second Major Managed Medicare Agreement For TONMYA
Agreement for the treatment of fibromyalgia in adults that is effective immediately, adding approximately 21 million Medicare lives (38% of approximately 55 million Medicare lives in the U.S.). Medicare coverage now
Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears
Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Seth Lederman told attendees at the Cantor Healthcare Conference that the company’s near-term focus is the commercial launch of TONMYA, its FDA-approved treatment for fibromyalgia in adults, while it advances development programs in Lyme disease prevention and
Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer
Mr. Englese’s leadership of Tonix’s commercial organization since 2024 has included the go-to-market strategy and U.S. launch of TONMYA®, with growth across sales, managed care, and patient accessBERKELEY HEIGHTS, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced the promotion of Thomas Englese to Chief Commercial Officer, effective immediately. Mr
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-27 | LEDERMAN SETH | +2,000 | $13.79 | $27,580 |
| 2026-08-20 | BAGGER RICHARD H | +1,000 | $12.6 | $12,600 |
| 2026-06-30 | SAENGER BRADLEY | +1,453 | $10.914 | $15,858 |
| 2026-06-12 | Taylor Carolyn E. | +1,415 | $10.55 | $14,928 |
| 2026-06-09 | LEDERMAN SETH | +5,000 | $11.79 | $58,950 |
| 2026-06-08 | Stillwell Richard Newcomb | +5,000 | $11.65 | $58,250 |
| 2026-05-12 | Stillwell Richard Newcomb | +22,700 | - | - |
| 2026-05-12 | Bell Margaret Smith | +22,700 | - | - |
| 2026-05-12 | Hunter James Randolph Jr | +22,700 | - | - |
| 2026-05-12 | Treco James | +22,700 | - | - |
| 2026-05-12 | Taylor Carolyn E. | +22,700 | - | - |
| 2026-05-12 | BAGGER RICHARD H | +22,700 | - | - |
| 2026-05-12 | GRANGE DAVID L | +22,700 | - | - |
| 2026-05-12 | OLUKOTUN ADEOYE Y | +22,700 | - | - |
| 2026-03-31 | LEDERMAN SETH | +5,000 | $12.62 | $63,100 |
| 2026-03-18 | LEDERMAN SETH | +15,000 | $14.89 | $223,350 |
| 2026-02-24 | MORRIS JESSICA EDGAR | +39,011 | - | - |
| 2026-02-24 | MORRIS JESSICA EDGAR | +39,012 | - | - |
| 2026-02-24 | SAENGER BRADLEY | +39,011 | - | - |
| 2026-02-24 | SAENGER BRADLEY | +39,012 | - | - |
| 2026-02-24 | SULLIVAN GREGORY M | +39,011 | - | - |
| 2026-02-24 | SULLIVAN GREGORY M | +39,012 | - | - |
| 2026-02-24 | Fogarty Siobhan | +39,011 | - | - |
| 2026-02-24 | Fogarty Siobhan | +39,012 | - | - |
| 2026-02-24 | LEDERMAN SETH | +134,503 | - | - |
| 2026-02-24 | LEDERMAN SETH | +134,504 | - | - |
| 2025-12-31 | SAENGER BRADLEY | +701 | $13.42 | $9,407 |